Previous 10 | Next 10 |
home / stock / cort / cort articles
Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released announced preliminary results from the prevalence phase of its ongoing...
In a new SEC filing on February 14, it was unveiled that Robb, Chief Business Officer at Corcept Therapeutics (NASDAQ:CORT), acquired stock options...
A substantial insider move unfolded on February 14, as Mokari, Chief Financial Officer at Corcept Therapeutics (NASDAQ:CORT), reported the acquisit...
A noteworthy insider acquisition was disclosed on February 14, as Lyon, Chief Accounting Officer at Corcept Therapeutics (NASDAQ:CORT), reported th...
A noteworthy insider acquisition was disclosed on February 14, as Guyer, Chief Development Officer at Corcept Therapeutics (NASDAQ:CORT), reported ...
Disclosed in a recent SEC filing, Joseph K Belanoff, Chief Executive Officer at Corcept Therapeutics (NASDAQ:CORT), made a strategic move by acquir...
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company...
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.0...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
Corcept Therapeutics Incorporated Website:
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84 th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enro...
2024-06-12 10:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $38.00 for CORT on 2024-06-12 07:45:00. The adjusted price target was set to $38.00. At the time of the announcement, CORT was trading at $32.79. The overall price target consensus is at $...